KR101676828B1 - A composition comprising an extract of Hippophae rhamnoides for treating or preventing a physiological stress, depression or dementia - Google Patents
A composition comprising an extract of Hippophae rhamnoides for treating or preventing a physiological stress, depression or dementia Download PDFInfo
- Publication number
- KR101676828B1 KR101676828B1 KR1020140140470A KR20140140470A KR101676828B1 KR 101676828 B1 KR101676828 B1 KR 101676828B1 KR 1020140140470 A KR1020140140470 A KR 1020140140470A KR 20140140470 A KR20140140470 A KR 20140140470A KR 101676828 B1 KR101676828 B1 KR 101676828B1
- Authority
- KR
- South Korea
- Prior art keywords
- stress
- extract
- vitamin
- levels
- preventing
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 67
- 239000000203 mixture Substances 0.000 title abstract description 47
- 240000000950 Hippophae rhamnoides Species 0.000 title description 7
- 235000003145 Hippophae rhamnoides Nutrition 0.000 title description 7
- 206010012289 Dementia Diseases 0.000 title 1
- 230000009894 physiological stress Effects 0.000 title 1
- 230000003340 mental effect Effects 0.000 claims abstract description 26
- 201000010099 disease Diseases 0.000 claims abstract description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 24
- 229940088594 vitamin Drugs 0.000 claims description 32
- 229930003231 vitamin Natural products 0.000 claims description 32
- 235000013343 vitamin Nutrition 0.000 claims description 32
- 239000011782 vitamin Substances 0.000 claims description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 30
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 26
- 239000004480 active ingredient Substances 0.000 claims description 13
- 230000036541 health Effects 0.000 claims description 12
- 208000019901 Anxiety disease Diseases 0.000 claims description 10
- 230000036506 anxiety Effects 0.000 claims description 10
- 230000002829 reductive effect Effects 0.000 claims description 9
- 206010022437 insomnia Diseases 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 6
- 235000013376 functional food Nutrition 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 235000015872 dietary supplement Nutrition 0.000 claims description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract description 66
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract description 60
- 229960003638 dopamine Drugs 0.000 abstract description 30
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 abstract description 29
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 abstract description 25
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 abstract description 25
- 210000004556 brain Anatomy 0.000 abstract description 24
- 229960002748 norepinephrine Drugs 0.000 abstract description 21
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 abstract description 21
- 229940076279 serotonin Drugs 0.000 abstract description 20
- 210000004369 blood Anatomy 0.000 abstract description 19
- 239000008280 blood Substances 0.000 abstract description 19
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 abstract description 13
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 abstract description 13
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 abstract description 13
- 235000019155 vitamin A Nutrition 0.000 abstract description 13
- 239000011719 vitamin A Substances 0.000 abstract description 13
- 229940045997 vitamin a Drugs 0.000 abstract description 13
- 241001465754 Metazoa Species 0.000 abstract description 12
- 238000002474 experimental method Methods 0.000 abstract description 10
- 230000002401 inhibitory effect Effects 0.000 abstract description 5
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000035882 stress Effects 0.000 description 68
- 102000004169 proteins and genes Human genes 0.000 description 36
- 108090000623 proteins and genes Proteins 0.000 description 36
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 description 22
- 230000000694 effects Effects 0.000 description 21
- 230000001965 increasing effect Effects 0.000 description 19
- 241000699670 Mus sp. Species 0.000 description 18
- 235000013305 food Nutrition 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 14
- 230000003247 decreasing effect Effects 0.000 description 12
- 235000013361 beverage Nutrition 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 239000002858 neurotransmitter agent Substances 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 230000035939 shock Effects 0.000 description 11
- 238000000034 method Methods 0.000 description 10
- 229940079593 drug Drugs 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 239000000796 flavoring agent Substances 0.000 description 9
- 235000019634 flavors Nutrition 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 239000013641 positive control Substances 0.000 description 8
- 229940026510 theanine Drugs 0.000 description 8
- 238000010171 animal model Methods 0.000 description 7
- 230000028327 secretion Effects 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 229940088597 hormone Drugs 0.000 description 6
- 239000005556 hormone Substances 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 208000020016 psychiatric disease Diseases 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 210000005013 brain tissue Anatomy 0.000 description 5
- 230000008645 cold stress Effects 0.000 description 5
- 229960003529 diazepam Drugs 0.000 description 5
- 229930003935 flavonoid Natural products 0.000 description 5
- 150000002215 flavonoids Chemical class 0.000 description 5
- 235000017173 flavonoids Nutrition 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- CFFZDZCDUFSOFZ-UHFFFAOYSA-N 3,4-Dihydroxy-phenylacetic acid Chemical compound OC(=O)CC1=CC=C(O)C(O)=C1 CFFZDZCDUFSOFZ-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 description 4
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 description 4
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 4
- 238000008157 ELISA kit Methods 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 230000002180 anti-stress Effects 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 235000013402 health food Nutrition 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000012046 mixed solvent Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 229960004793 sucrose Drugs 0.000 description 4
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 3
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- FMMWHPNWAFZXNH-UHFFFAOYSA-N Benz[a]pyrene Chemical compound C1=C2C3=CC=CC=C3C=C(C=C3)C2=C2C3=CC=CC2=C1 FMMWHPNWAFZXNH-UHFFFAOYSA-N 0.000 description 3
- 102400000739 Corticotropin Human genes 0.000 description 3
- 101800000414 Corticotropin Proteins 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 235000019501 Lemon oil Nutrition 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 244000269722 Thea sinensis Species 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- -1 amine metabolite of dopamine Chemical class 0.000 description 3
- 239000002249 anxiolytic agent Substances 0.000 description 3
- 230000000949 anxiolytic effect Effects 0.000 description 3
- 229940049706 benzodiazepine Drugs 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 3
- 229960000258 corticotropin Drugs 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 229940094952 green tea extract Drugs 0.000 description 3
- 235000020688 green tea extract Nutrition 0.000 description 3
- 210000003016 hypothalamus Anatomy 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 229960001375 lactose Drugs 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000010501 lemon oil Substances 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 229960001855 mannitol Drugs 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 235000013616 tea Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102000011727 Caspases Human genes 0.000 description 2
- 108010076667 Caspases Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 102000005915 GABA Receptors Human genes 0.000 description 2
- 108010005551 GABA Receptors Proteins 0.000 description 2
- 102000004300 GABA-A Receptors Human genes 0.000 description 2
- 108090000839 GABA-A Receptors Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010062767 Hypophysitis Diseases 0.000 description 2
- DATAGRPVKZEWHA-UHFFFAOYSA-N L-gamma-glutamyl-n-ethylamine Natural products CCNC(=O)CCC(N)C(O)=O DATAGRPVKZEWHA-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 240000004580 Magnolia hypoleuca Species 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 210000004100 adrenal gland Anatomy 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 210000004727 amygdala Anatomy 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- OUGIDAPQYNCXRA-UHFFFAOYSA-N beta-naphthoflavone Chemical compound O1C2=CC=C3C=CC=CC3=C2C(=O)C=C1C1=CC=CC=C1 OUGIDAPQYNCXRA-UHFFFAOYSA-N 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 229940077731 carbohydrate nutrients Drugs 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 229960004782 chlordiazepoxide Drugs 0.000 description 2
- ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 230000002964 excitative effect Effects 0.000 description 2
- 239000011536 extraction buffer Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 229960001031 glucose Drugs 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000004179 hypothalamic–pituitary–adrenal axis Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 229940041476 lactose 100 mg Drugs 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 238000001690 micro-dialysis Methods 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000001009 nucleus accumben Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- OPGPFZQBCIAFLI-UHFFFAOYSA-N obovatol Chemical compound OC1=CC(CC=C)=CC(OC=2C=CC(CC=C)=CC=2)=C1O OPGPFZQBCIAFLI-UHFFFAOYSA-N 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 210000003635 pituitary gland Anatomy 0.000 description 2
- 210000003814 preoptic area Anatomy 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000001624 sedative effect Effects 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 230000004938 stress stimulation Effects 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- LPLLVINFLBSFRP-UHFFFAOYSA-N 2-methylamino-1-phenylpropan-1-one Chemical compound CNC(C)C(=O)C1=CC=CC=C1 LPLLVINFLBSFRP-UHFFFAOYSA-N 0.000 description 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 206010002869 Anxiety symptoms Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- TXVHTIQJNYSSKO-UHFFFAOYSA-N BeP Natural products C1=CC=C2C3=CC=CC=C3C3=CC=CC4=CC=C1C2=C34 TXVHTIQJNYSSKO-UHFFFAOYSA-N 0.000 description 1
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 244000293323 Cosmos caudatus Species 0.000 description 1
- 235000005956 Cosmos caudatus Nutrition 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241001117772 Elaeagnaceae Species 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 208000011688 Generalised anxiety disease Diseases 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 206010029412 Nightmare Diseases 0.000 description 1
- 241000277275 Oncorhynchus mykiss Species 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 229940122907 Phosphatase inhibitor Drugs 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 241001032481 Protium heptaphyllum Species 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 208000010340 Sleep Deprivation Diseases 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000037328 acute stress Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- FSLPMRQHCOLESF-UHFFFAOYSA-N alpha-amyrenol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C)C(C)C5C4=CCC3C21C FSLPMRQHCOLESF-UHFFFAOYSA-N 0.000 description 1
- FSLPMRQHCOLESF-SFMCKYFRSA-N alpha-amyrin Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C FSLPMRQHCOLESF-SFMCKYFRSA-N 0.000 description 1
- SJMCNAVDHDBMLL-UHFFFAOYSA-N alpha-amyrin Natural products CC1CCC2(C)CCC3(C)C(=CCC4C5(C)CCC(O)CC5CCC34C)C2C1C SJMCNAVDHDBMLL-UHFFFAOYSA-N 0.000 description 1
- 229960004538 alprazolam Drugs 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 229940125713 antianxiety drug Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006400 anxiety behaviour Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- JFSHUTJDVKUMTJ-QHPUVITPSA-N beta-amyrin Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C JFSHUTJDVKUMTJ-QHPUVITPSA-N 0.000 description 1
- QQFMRPIKDLHLKB-UHFFFAOYSA-N beta-amyrin Natural products CC1C2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C)CCC1(C)C QQFMRPIKDLHLKB-UHFFFAOYSA-N 0.000 description 1
- PDNLMONKODEGSE-UHFFFAOYSA-N beta-amyrin acetate Natural products CC(=O)OC1CCC2(C)C(CCC3(C)C4(C)CCC5(C)CCC(C)(C)CC5C4=CCC23C)C1(C)C PDNLMONKODEGSE-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 1
- 229960002495 buspirone Drugs 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 229940037769 calcium carbonate 100 mg Drugs 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229940069647 citric acid 1000 mg Drugs 0.000 description 1
- 229960003120 clonazepam Drugs 0.000 description 1
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 208000029364 generalized anxiety disease Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 206010020765 hypersomnia Diseases 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960004391 lorazepam Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000001554 moculating effect Effects 0.000 description 1
- 230000001730 monoaminergic effect Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- 230000009125 negative feedback regulation Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 230000002474 noradrenergic effect Effects 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001671 psychotherapy Methods 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000004799 sedative–hypnotic effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 230000028016 temperature homeostasis Effects 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- RMNIZOOYFMNEJJ-UHFFFAOYSA-K tripotassium;phosphate;hydrate Chemical compound O.[K+].[K+].[K+].[O-]P([O-])([O-])=O RMNIZOOYFMNEJJ-UHFFFAOYSA-K 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940033203 vitamin b6 0.5 mg Drugs 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Abstract
본 발명은 비타민나무 추출물을 함유하는 조성물에 관한 것으로, 정신적 스트레스를 유발한 마우스를 이용한 동물 실험에서 마우스의 뇌 및 혈중 도파민(dopamine), 노르아드레날린(noradrenaline) 및 코르티코스테론(corticosterone)의 수준(level)을 저하시키고, 세로토닌(serotonin) 의 수준(level)이 증가시킴을 확인하여 정신적 스트레스 관련 질환에 대한 억제, 예방 및 치료에 유용함을 확인하였다. The present invention relates to a composition containing a vitamin A tree extract, wherein the level of dopamine, noradrenaline, and corticosterone in the brain and blood of a mouse in an animal experiment using a mouse causing mental stress level and lowering the level of serotonin, thereby confirming that the compound is useful for inhibiting, preventing and treating mental stress related diseases.
Description
본 발명의 비타민나무 추출물을 유효성분으로 함유하는 조성물은 정신적 스트레스를 유발한 마우스를 이용한 동물 실험에서 마우스의 뇌 및 혈중 도파민, 노르아드레날린, 세로토닌(5-HT), 및 코르티코스테론 수준을 감소시킴으로서, 정신적 스트레스에 저항하는 효과가 탁월하므로 스트레스 관련 질환 또는 피로에 대한 억제, 예방 및 개선에 유용하다. The composition containing the vitamin-tree extract of the present invention as an active ingredient can be used as an active ingredient by reducing the levels of brain and blood dopamine, noradrenaline, serotonin (5-HT), and corticosterone in mice in an animal experiment using a mouse that induced mental stress , And is effective in suppressing, preventing and improving stress-related diseases or fatigue because it is excellent in resistance to mental stress.
[문헌 1] Charney, D. S. : Neuroanatomical circuits moculating fear and anxiety behaviors. Acta. Psychiatr. Scand. Suppl. 417, 38(2003); [1] Charney, D. S.: Neuroanatomical circuits moculating fear and anxiety behaviors. Acta. Psychiatr. Scand. Suppl. 417, 38 (2003);
[문헌 2]Millan, M. J. : The neurobiology and control of anxious states. Prog. Neurobiol. 70, 83 (2003)[2] Millan, M. J.: The neurobiology and control of anxious states. Prog. Neurobiol. 70, 83 (2003)
[문헌 3]Sugimoto, Y, et al., : Effects of extracts and neferine from the embryo of Nelumbo nucifera seeds on the central nervous system. Phytomedicin. 15, 1117 (2008); [3] Sugimoto, Y, et al.,: Effects of extracts and nephrine from the embryo of Nelumbo nucifera seeds on the central nervous system. Phytomedicin. 15,1117 (2008);
[문헌 4] Arago, G. F., et al., : A possible mechanism for anxiolytic and antidepressant effects of alpha and beta-amyrin from Protium heptaphyllum (Aubl.) March. Pharmacol. Biochem. Behav. 85, 827 (2006).[4] Arago, G. F., et al.,: A possible mechanism for anxiolytic and antidepressant effects of alpha and beta-amyrin from Protium heptaphyllum (Aubl.) March. Pharmacol. Biochem. Behav. 85, 827 (2006).
[문헌 5]Kalivas, P. W. and Duffy, P. : Selective activation of dopamine transmission in the shell of the nucleus accumbens by stress. Brain Res. 675, 325 (1995); [Literature 5] Kalivas, P. W. and Duffy, P.: Selective activation of dopamine transmission in the nucleus accumbens by stress. Brain Res. 675, 325 (1995);
[문헌 6] Tidey, J. W. and Miczek, K. A. : Social defeat stress selectively alters mesocorticolimbic dopamine release: an in vivo microdialysis study. Brain Res. 721, 140 (1996).[6] Tidey, J. W. and Miczek, K. A. Social defeat stress selectively alters mesocorticolimbic dopamine release: an in vivo microdialysis study. Brain Res. 721,140 (1996).
[문헌 7]Gesto, M., Soengas, J. L. and Miguez, J. M. : Acute and prolonged stress responses of brain monoaminergic activity and plasma cortisol levels in rainbow trout are modified by PAHs (naphthalene, beta-naphthoflavone and benzo(a)pyrene) treatment. Aquat. Toxicol. 86, 341 (2008).[7] Gesto, M., Soengas, JL and Miguez, JM: Acute and prolonged stress responses of brain monoaminergic activity and plasma cortisol levels in rainbow trout modified by PAHs (naphthalene, beta-naphthoflavone and benzo (a) pyrene) treatment. Aquat. Toxicol. 86, 341 (2008).
[문헌 8]Buffalari, D. M. and Grace, A. A. : Chronic cold stress increases excitatory effects of norepinephrine on spontaneous and evoked activity of basolateral amygdala neurons. Int. J. Neuropsychopharmacol. 12, 95 (2009).[문헌 9] Saito, T., et al., : Effect of chronic cold exposure on noradrenergic modulation in the preoptic area of thermoreulation in freely moving rats. Life Sci. 83, 79 (2008).[8] Buffalari, D. M. and Grace, A. A. Chronic cold stress increases excitatory effects of norepinephrine on spontaneous and evoked activity of basolateral amygdala neurons. Int. J. Neuropsychopharmacol. 12, 95 (2009). [9] Saito, T., et al.,: Effect of chronic cold exposure on noradrenergic modulation in the preoptic area of thermoregulation in freely moving rats. Life Sci. 83, 79 (2008).
[문헌 10]Lapiz-bluhm, M. D., et al., : Chronic intermittent cold stress and serotonin depletion induce deficits of reversal learning in an attentional set-shifting test in rats. Psychopharmacology (Berl) 202, 329 (2009).[Literature 10] Lapiz-bluhm, M. D., et al.,: Chronic intermittent cold stress and serotonin depletion induce deficits of reversal learning in an attentional set-shifting test in rats. Psychopharmacology (Berl) 202,329 (2009).
[문헌 11]Parker, C. C. et al., : Restraint stress and exogenous corticosterone differentially alter sensitivity to the sedative-hypnotic effects of ethanol in inbred long-sleep and inbred short-sleep mice. 녹차추출물과 테아닌 복합물의 신경전달물질 조절을 통한 항스트레스 효과 249 Vol. 53, No. 5, 2009 Alcohol. 42, 477 (2008)Parker, C. C. et al.,: Restraint stress and exogenous corticosterone differentially altered sensitivity to the sedative-hypnotic effects of ethanol in inbred long-sleep and inbred short-sleep mice. Antistress effect through neurotransmitter regulation of green tea extract and theanine complex 249 Vol. 53, No. 5, 2009 Alcohol. 42, 477 (2008)
[문헌 12]Swiergiel, A. H., et al., : Effects of chlordiazepoxide on footshock- and corticotropin-releasing factor-induced increases in cortical and hypothalamic norepinephrine secretion in rats. Neurochem. Int. 52, 1220 (2008)[12] Swiergiel, A. H., et al.,: Effects of chlordiazepoxide on footshock- and corticotropin-releasing factor-induced increases in cortical and hypothalamic norepinephrine secretion in rats. Neurochem. Int. 52, 1220 (2008)
[문헌 13]Komiya, M., Takeuchi, T. and Harada, E. : Lemon oil vapor causes an anti-stress effect via modulating the 5-HT and DA activities in mice. Behav. Brain Res. 17. 172, 240 (2006).[Literature 13] Komiya, M., Takeuchi, T. and Harada, E.: Lemon oil vapor causes an anti-stress effect via modulating the 5-HT and activities in mice. Behav. Brain Res. 17, 172, 240 (2006).
[문헌 14] Seo, J. et al., : Anxiolytic -like effects of obovatol isolated from Magnolia obovata:Involvement of GABA/benzodiazepine receptors complex. Progress in Neuro-Psychopharmacology & Biological Psychiatry 31, 1363 (2007) [14] Seo, J. et al.,: Anxiolytic -like effects of obovatol isolated from Magnolia obovata: Involvement of GABA / benzodiazepine receptors complex. Progress in Neuro-Psychopharmacology & Biological Psychiatry 31, 1363 (2007)
[문헌 15] 대한민국 특허등록 10-0008014호[Document 15] Korean Patent Registration No. 10-0008014
[문헌 16] 대한민국 특허등록 10-0012695호[Document 16] Korean Patent Registration No. 10-0012695
[문헌 17] 대한민국 특허등록 10-0008675호[Document 17] Korean Patent Registration No. 10-0008675
[문헌 18] Journal of antimicrobial chemotherapy, L. C. Chiang, W. Chiang, M. C. Liu and C. C. Lin, Vol. 52, pp 194~198, 2003[Literature 18] Journal of antimicrobial chemotherapy, L. C. Chiang, W. Chiang, M. C. Liu and C. C. Lin, Vol. 52, pp 194-198, 2003
[문헌 19]J. Agric. Food Chem., Vol.47, pp 3480~3488[Literature 19] J. Agric. Food Chem., Vol. 47, pp 3480-3488
[문헌 20] J. of Chromatography A, Chu Chen, 1154, pp 250~259
[Literature 20] J. of Chromatography A, Chu Chen, 1154, pp. 250 to 259
본 발명은 비타민나무 추출물을 유효성분으로 함유하는 정신적 스트레스 관련 질환의 치료 및 예방을 위한 조성물에 관한 것이다.The present invention relates to a composition for the treatment and prevention of mental stress-related diseases containing vitamin-tree extract as an active ingredient.
스트레스는 예로부터 만병의 근원으로 일컬어지고 있으며, 특히 현대사회에서는 학업, 업무, 결혼, 육아 등의 사회적 요인, 날씨, 교통 등의 주변 환경적 요인 등 다양한 원인으로 인하여 남녀노소를 불문하고 과도하게 발생하고 있기 때문에 매우 중요한 사회적 문제로 인식되고 있다. Stress has been referred to as the source of all diseases since ancient times. Especially in modern society, social factors such as academic work, work, marriage, child care, environmental factors such as weather and traffic, And it is recognized as a very important social problem.
우리 사회가 급격히 발전하고 다변화 되면서 현대인에게 요구되는 역할들이 증대됨에 따라, 여러 가지 스트레스로 인한 범불안 장애 및 정신질환을 호소하는 사람들이 증가하고 있다. 보건복지부가 발표한 '2006년도 정신질환실태 역학조사'에 따르면, 2006년 1년간 한 가지 이상의 정신질환 경험 인구비율인 '정신질환 일년 유병율'은 17.1 %로 나타났다. 이는 18세 이상 64세 이하 성인 6명 중 1명 꼴이며, 2006년 현재 평생동안 한가지 이상의 정신질환 경험 인구비율인 '정신질환 평생 유병율'은 성인 3명 중 1명인 30%로 나타났다. 최근 과도한 학구열 또는 각종 스트레스로 인한 청소년 정신질환이 늘고 있는 추세를 감안한다면 전체 인구의 유병율은 더욱 높다고 할 수 있겠다.As our society rapidly develops and diversifies, the number of people who complain of generalized anxiety disorder and mental illness due to various stresses are increasing as the roles required for modern people are increased. According to the 2006 Mental Disease Epidemiology Survey released by the Ministry of Health and Welfare, the prevalence rate of mental illness in the past year was 17.1%. This is one in six adults between the ages of 18 and 64, and in 2006, the lifetime prevalence of mental illness, which is the proportion of people with at least one mental illness during the lifetime, was 30%, or one in three adults. Considering the recent trend of excessive mental illness due to excessive school-age or various stresses, the prevalence rate of the whole population is higher.
불안증과 스트레스를 유발하는 데는 생체내 신경전달물질 및 호르몬이 밀접한 관련이 있다. 외부 자극 및 스트레스에 대해 체내에서는 시상하부에서 신경전달물질 및 호르몬의 분비를 관장하는데, 시상하부에서 중추신경계로의 신호전달을 통하여 각 신경말단에서 도파민(dopamine) 및 노르아드레날린(noradrenaline), 세로토닌(serotonin) 등과 같은 신경전달물질의 유리를 조절함으로써 감정상태, 심박동수, 혈압 및 골격근의 혈류 증가 등과 같은 생리활성을 조절하게 된다. 그리고 hypothalamic-pituitary-adrenal(HPA) axis system 을 통하여 혈액으로의 호르몬 분비가 이루어지는데, 이는 시상하부에서 뇌하수체, 부신으로 이어지는 호르몬의 circulation system 으로, 어떠한 외부 자극 또는 스트레스를 받게 되면, 시상하부에서 부신피질 자극 호르몬 방출인자(corticotropin-releasing factor; CRF)를 분비하게 된다. 뇌하수체의 CRF 와 특이적으로 결합하는 수용체에 이 호르몬이 결합하게 되면 부신피질자극호르몬 (adrenocorticotropic hormone;ACTH)을 분비한다. ACTH는 혈액 및 림프절을 통해 부신에 도착하게 되어 피질에서 코르티코스테론(corticosterone)과 같은 스테로이드 호르몬과 수질에서 카테콜아민(catecholamine) 류의 신경전달물질을 혈액으로 방출하여, 심박동수, 혈압 및 에너지 대사 등의 조절에 관여하게 되며, 역조절 피드-백 기전(negative feedback regulation)을 통하여 이들 인자들의 분비를 조절한다.(1,2Charney, D. S. : Neuroanatomical circuits moculating fear and anxiety behaviors. Acta. Psychiatr. Scand. Suppl. 417, 38(2003); 2) Millan, M. J. : The neurobiology and control of anxious states. Prog. Neurobiol. 70, 83 (2003).)Anxiety and stress are closely related to in vivo neurotransmitters and hormones. In response to external stimuli and stress, the body controls the secretion of neurotransmitters and hormones in the hypothalamus. The signal from the hypothalamus to the central nervous system causes dopamine and noradrenaline, serotonin serotonin, and the like, thereby regulating physiological activities such as emotional state, heart rate, blood pressure, and blood flow increase of skeletal muscle. The hormone secretion from the hypothalamus to the pituitary gland and the adrenal glands is a circulation system through the hypothalamic-pituitary-adrenal (HPA) axis system. When any external stimulus or stress is applied, Secretion of corticotropin-releasing factor (CRF). When the hormone binds to a receptor that specifically binds to the CRF of the pituitary gland, it secretes adrenocorticotropic hormone (ACTH). ACTH arrives at the adrenal gland through the blood and lymph nodes, releasing corticosterone-like steroid hormones and catecholamine-like neurotransmitters from the cortex to the blood, thereby releasing heart rhythm, blood pressure and energy metabolism And regulate the secretion of these factors through negative feedback regulation (1,2 Kharney, DS: Neuroanatomical circuits: moculating fear and anxiety behaviors. Acta. Psychiatr. Scand. 417, 38 (2003), 2) Millan, MJ: The neurobiology and control of anxious states. Prog. Neurobiol. 70, 83 (2003).)
현재 임상에서는 약물치료와 장기적 정신치료를 병행해 불안증을 치료하고 있으며, 약물치료의 경우에는 주로 디아제팜(diazepam), 로라제팜(lorazepam), 클로나제팜(clonazepam), 알프러졸람(alprazolam)과 같은 벤조디아제팜(benzodiazepine) 계통의 항불안 약물들을 주로 사용되고 있고, 아자피론(azapirone) 계의 부스피론(buspirone)은 선택적으로 세로토닌(serotonin) 수용체에 작용하여서 선택적으로 불안증후를 완화시킬 수 있는 약물로 사용이 되고 있다. 또한 최근에는 이러한 약물의 부작용을 보완할 수 있는 천연물로부터 유래한 스트레스 조절물질의 연구가 활발히 진행되어 오고 있으며3,4Sugimoto, Y, et al., : Effects of extracts and neferine from the embryo of Nelumbo nucifera seeds on the central nervous system. Phytomedicin. 15, 1117 (2008); 4) Arago, G. F., et al., : A possible mechanism for anxiolytic and antidepressant effects of alpha and beta-amyrin from Protium heptaphyllum (Aubl.) March. Pharmacol. Biochem. Behav. 85, 827 (2006).) dopamine과 serotonin이 주요 조절 물질로서 호르몬으로서 연구되고 있다. In clinical practice, medication is combined with long-term psychotherapy to treat anxiety. In the case of medication, diazepam, lorazepam, clonazepam, alprazolam, Benzodiazepine-based anti-anxiety drugs are mainly used, and azapirone-based buspirone selectively acts on serotonin receptors to selectively relieve post-anxiety symptoms. . Recently, studies on stress-regulating substances derived from natural materials that can complement the side effects of these drugs have been actively carried out. 3,4 Sugimoto, Y, et al.: Effects of extracts and nephrine from the embryo of Nelumbo nucifera seeds on the central nervous system. Phytomedicin. 15,1117 (2008); 4) Arago, G. F., et al.,: A possible mechanism for anxiolytic and antidepressant effects of alpha and beta-amyrin from Protium heptaphyllum (Aubl.) March. Pharmacol. Biochem. Behav. 85, 827 (2006).) Dopamine and serotonin have been studied as hormones as the main regulators.
스트레스와 관련된 신경전달물질의 변화와 불안/스트레스와의 관계를 살펴보면, 우선 도파민(dopamine)의 경우 카테콜아민(catecholamine) 형태의 신경전달물질의 일종으로 뇌신경 세포의 흥분 전달역할을 하며, 주의 집중, 긴장, motivation 상태를 주로 조절한다고 알려져 있고, 과다하게 분비될 경우 정신분열과 같은 질환을 유발하게 되며, 부족하게 될 경우 파킨슨 질병과 같은 운동장애를 유발한다고 알려져 있다. 도파민 시스템(Dopamine system) 의 경우 스트레스에 대해 민감하게 반응을 하며, 여러 가지 급성 스트레스는 도파민(dopamine)의 유리를 증가시킨다고 보고되어 있으며,7,8Kalivas, P. W. and Duffy, P. : Selective activation of dopamine transmission in the shell of the nucleus accumbens by stress. Brain Res. 675, 325 (1995); 8) Tidey, J. W. and Miczek, K. A. : Social defeat stress selectively alters mesocorticolimbic dopamine release: an in vivo microdialysis study. Brain Res. 721, 140 (1996).) 나프탈렌(naphthalene), 베타나프토플라본(betanaphthoflavone) 및 벤조피렌(benzopyrene)과 같은 엔도톡신(endotoxin)에 의한 스트레스에 급, 만성으로 노출되었을 경우에도 도파민(dopamine)과 도파민(dopamine)의 아민 대사체(amine metabolites)인 DOPAC(3,4-dihydroxyphenylacetic acid) 등이 증가한다고 보고되어 있다.9Gesto, M., Soengas, J. L. and Miguez, J. M. : Acute and prolonged stress responses of brain monoaminergic activity and plasma cortisol levels in rainbow trout are modified by PAHs (naphthalene, beta-naphthoflavone and benzo(a)pyrene) treatment. Aquat. Toxicol. 86, 341 (2008).) The relationship between stress-related neurotransmitter changes and anxiety / stress is as follows: First, dopamine is a type of catecholamine-type neurotransmitter that acts as an excitatory transfer of neuronal cells, , it is known to regulate the motivation state. Excessive secretion leads to diseases such as schizophrenia. If it is insufficient, it is known to cause movement disorders such as Parkinson's disease. The dopamine system is sensitive to stress and various acute stresses have been reported to increase dopamine release, 7, Kalivas, PW and Duffy, P.: Selective activation of dopamine transmission in the shell of the nucleus accumbens by stress. Brain Res. 675, 325 (1995); 8) Tidey, J. W. and Miczek, K. A. Social defeat stress selectively alters mesocorticolimbic dopamine release: an in vivo microdialysis study. Brain Res. 721, 140 (1996).) Even when exposed to chronic and endotoxin-induced stresses such as naphthalene, betanaphthoflavone and benzopyrene, dopamine and dopamine DOPAC (3,4-dihydroxyphenylacetic acid), which is an amine metabolite of dopamine, has been reported to increase in the brain. [9] Gesto, M., Soengas, JL and Miguez, JM: Acute and prolonged stress responses of brain monoaminergic activity and plasma cortisol levels in rainbow trout are modified by PAHs (naphthalene, beta-naphthoflavone and benzo (a) pyrene) treatment. Aquat. Toxicol. 86, 341 (2008).)
노르아드레날린(Noradrenaline) 또한, HPA axis system 에 의해 스트레스에 적응하기 위하여 부신피질에서 분비되는 신경전달물질로, 교감신경을 활성화시켜 혈압, 심박동수, 호흡수 등 스트레스나 불안감이 생길 경우 생리적으로 나타나는 현상을 조절하는 역할을 한다. 콜드 스트레스(Cold stress)를 통하여 스트레스 상태를 실험동물에 유도할 경우 노르에피네프린(norepinephrine) 유리를 증가시키고, basolateral amygdala 의 neuronal activity 를 활성화시킨다고 보고되어 있으며,10Buffalari, D. M. and Grace, A. A. : Chronic cold stress increases excitatory effects of norepinephrine on spontaneous and evoked activity of basolateral amygdala neurons. Int. J. Neuropsychopharmacol. 12, 95 (2009).) Saito 등이 발표한 연구에도 급성 cold stress 상태에서 noradrenaline의 분비가 증가하여 medial preoptic area 를 조절하여 체온을 유지한다고 알려졌다.1111) Saito, T., et al., : Effect of chronic cold exposure on noradrenergic modulation in the preoptic area of thermoreulation in freely moving rats. Life Sci. 83, 79 (2008).) Noradrenaline is also a neurotransmitter secreted by the adrenal cortex to adapt to stress by the HPA axis system. It activates the sympathetic nervous system and causes physiological symptoms when stress or anxiety such as blood pressure, heart rate, . It has been reported that inducing stress in experimental animals through cold stress increases norepinephrine release and activates neuronal activity of basolateral amygdala. 10Buffalari, DM and Grace, AA: Chronic cold stress increases excitatory effects of norepinephrine on spontaneous and evoked activity of basolateral amygdala neurons. Int. J. Neuropsychopharmacol. In a study by Saito et al. (2004), it was reported that noradrenalin secretion increased in acute cold stress and maintained the body temperature by controlling the medial preoptic area.1111 Saito, T., et al., Effects of chronic cold exposure on noradrenergic modulation in the preoptic area of thermoregulation in freely moving rats. Life Sci. 83, 79 (2008).
세로토닌(Serotonin)의 경우 간헐적 cold stress를 유도하였을 경우 serotonin의 level 이 감소되며, 세로토닌(serotonin) 결핍이 학습능력과 주의력을 떨어뜨린다는 연구결과가 보고되어 있으며,12Lapiz-bluhm, M. D., et al., : Chronic intermittent cold stress and serotonin depletion induce deficits of reversal learning in an attentional set-shifting test in rats. Psychopharmacology (Berl) 202, 329 (2009).) 선천적으로 수면시간이 긴 마우스와 짧은 마우스를 이용하여 구속 스트레스(restraint stress)를 유도하여 corticosterone의 level과 ethanol의 안정작용(sedative)이 미치는 영향을 연구한 결과에서도 급성 및 반복 구속 실험에서 corticosterone 의 level 이 상승한 것을 확인할 수 있었다.13Parker, C. C. et al., : Restraint stress and exogenous corticosterone differentially alter sensitivity to the sedative-hypnotic effects of ethanol in inbred long-sleep and inbred short-sleep mice. 녹차추출물과 테아닌 복합물의 신경전달물질 조절을 통한 항스트레스 효과 249 Vol. 53, No. 5, 2009 Alcohol. 42, 477 (2008)).Serotonin has been reported to decrease serotonin levels when intermittent cold stress is induced, and serotonin deficiency may decrease learning and attention. 12Lapiz-bluhm, MD, et al. ,: Chronic intermittent cold stress and serotonin depletion induce deficits of reversible learning in an attentional set-shifting test in rats. Psychopharmacology (Berl) 202, 329 (2009).) The effects of corticosterone levels and sedative effects of ethanol on restraint stress induced by long-sleeping mice and short mice The results of the present study showed that corticosterone levels were elevated in acute and repeated constipation experiments. 13 Parker, CC et al.,: Restraint stress and exogenous corticosterone differentially altered sensitivity to the sedative-hypnotic effects of ethanol in inbred long-sleep and inbred short-sleep mice. Antistress effect through neurotransmitter regulation of green tea extract and theanine complex 249 Vol. 53, No. 5, 2009 Alcohol. 42, 477 (2008)).
그리고 현재 임상적으로 흔히 사용되는 항불안 약물인 benzodiazepine 류의 약물들을 사용하여 본 실험에서 측정한 신경전달 물질들의 level을 측정해 본 연구결과들에 의하면, electric foot shock 과 microdialysis 를 이용, 뇌내에 CRF를 주입할 경우 비처리군인 대조군에 비하여 norepinephrine이 300% 이상 수치가 상승하였으며, 대표적인 benzodiazepine 계통 약물인 chlordiazepoxide를 5 mg/kg 복강주사로 처리하였을 경우 상승된 norepinephrine 수치를 유의적으로 감소시키는 것으로 밝혀졌다.14Swiergiel, A. H., et al., : Effects of chlordiazepoxide on footshock- and corticotropin-releasing factor-induced increases in cortical and hypothalamic norepinephrine secretion in rats. Neurochem. Int. 52, 1220 (2008).) 그러나 이러한 약물들은 지나친 안정효과(sedative effect), 근이완,불면증, 약물의존성등을 초래하므로 이를 극복하기 위해 천연물을 이용한 연구들이 진행되고 있다. Komiya 등은 lemon oil 향을 이용한 anti-stress 효능을 마우스의 serotonin과 dopamine 활성 측정를 통하여 측정한 결과, lemon oil 향이 dopamine의 활성을 억제하며, serotonergic neuron 활성을 증가시켜 항스트레스 효능이 있음을 보였으며,15) Oh16Komiya, M., Takeuchi, T. and Harada, E. : Lemon oil vapor causes an anti-stress effect via modulating the 5-HT and DA activities in mice. Behav. Brain Res. 17. 172, 240 (2006).등은 후박(Magnolia obovata) 추출물에서 GABA/benzodiazepine receptor가 연관된 항불안 효능을 보고한 바 있다(16) Seo, J. et al., : Anxiolytic -like effects of obovatol isolated from Magnolia obovata:Involvement of GABA/benzodiazepine receptors complex. Progress in Neuro-Psychopharmacology & Biological Psychiatry 31, 1363 (2007). 이와 같은 연구결과들을 비교할 때 스트레스/불안 유도시 도파민(dopamine), 노르아드레날린(noradrenaline) 및 코르티코스테론(corticosterone)의 수준(level)이 증가하고, 세로토닌(serotonin) 의 수준(level)이 감소하는 것을 알 수 있었다.
In the present study, we measured the levels of neurotransmitters measured using the benzodiazepine drugs, which are commonly used antibiotics, clinically. In this study, we used electric foot shock and microdialysis, , Norepinephrine was increased by more than 300% compared with the control group, and it was found that treatment with 5 mg / kg of chlordiazepoxide, a representative benzodiazepine-based drug, significantly decreased elevated norepinephrine levels .14 Swiergiel, AH, et al.,: Effects of chlordiazepoxide on footshock- and corticotropin-releasing factor-induced increases in cortical and hypothalamic norepinephrine secretion in rats. Neurochem. Int. 52, 1220 (2008).) However, these drugs cause excessive sedative effects, muscle relaxation, insomnia, drug dependence, and so on. Komiya et al. Measured anti-stress efficacy using lemon oil flavor by measuring serotonin and dopamine activity in mice. As a result, lemon oil inhibited the activity of dopamine, increased serotonergic neuron activity, and showed antistress efficacy. 15) Oh16Komiya, M., Takeuchi, T. and Harada, E.: Lemon oil vapor causes an anti-stress effect via modulating the 5-HT and activities in mice. Behav. Brain Res. 17, 172, 240 (2006) reported an anxiolytic efficacy associated with the GABA / benzodiazepine receptor in Magnolia obovata extract. (16) Seo, J. et al., Anxiolytic -like effects of obovatol isolated from Magnolia obovata: Involvement of GABA / benzodiazepine receptors complex. Progress in Neuro-Psychopharmacology & Biological Psychiatry 31, 1363 (2007). Comparing the results of these studies suggests that levels of dopamine, noradrenaline and corticosterone levels increase and levels of serotonin decrease when stress / anxiety is induced .
종래의 기술로 대한민국 특허등록 10-0008014호에서는 시상하부-뇌하수체-부신 축의 기본 활성을 감소시켜 수면 및 수면-관련 거동에 영향을 주는 방법에 관해 개시하여 수면과 스트레스의 주요 대사산물인 코르티졸과의 관계를 확인하였다. 또한, 대한민국 특허등록 10-0012695호에서는 노근추출물을 함유하는 스트레스 완화, 피로회복 또는 운동수행능력 증강용 식품조성물에 관하여 개시하였고, 대한민국 특허등록 10-0008675호에서는 노근, 모과 및 미강 추출물을 함유하는 피로회복 또는 스트레스 억제용 식품 조성물에 관하여 개시하였으나, 천연식물자원을 이용하여 수면부족 및 스트레스와 관련된 기술 및 연구는 미미하다.
Korean Patent Registration No. 10-0008014 discloses a method for decreasing the basal activity of the hypothalamus-pituitary-adrenal axis and influencing sleep- and sleep-related behaviors with conventional techniques, Relationship. Korean Patent Registration No. 10-0012695 discloses a food composition for improving stress relief, fatigue recovery, or exercise performance, which comprises a caspase extract. Korean Patent Registration No. 10-0008675 discloses a composition containing a caspase, Fatigue recovery, or stress. However, techniques and researches related to sleep deprivation and stress using natural plant resources are insignificant.
비타민나무(일명, 갈매모리수나무 또는 산자나무로 지칭됨; Hippophae rhamnoides)는 보리수과(Elaeagnaceae)의 식물로서, 영국 동부와 남동부 해안의 모래언덕에 많으며, 유럽과 아시아의 산악지대, 중국의 내몽고지역과 러시아의 시베리아지역, 캐나다의 오지 등의 저온이며 척박한 지역에 자생하는 식물로서, 식물 유래 플라보노이드나 당화 플라보노이드의 약리 활성에 대해서는 많이 알려져 있다(Journal of antimicrobial chemotherapy, L. C. Chiang, W. Chiang, M. C. Liu and C. C. Lin, Vol. 52, pp 194~198, 2003). 여러 연구자들에 의하여 산자나무의 유효성분에 관련된 연구가 많이 진행되어 왔다. 특히, 산자나무 열매에서 각종 천연 바타민(A, B, C, E, P, K)의 함량을 정량 및 정성분석하였으며, 각종 아미노산들의 함량 및 각종 유용 금속류의 함유량을 분석하였다. 또한, 각종 영양소의 함유량에 관한 연구와 산자나무 열매를 식품으로 이용하기 위한 기초자료로 열매관련 물성 연구가 진행되었다(J. Agric. Food Chem., Vol.47, pp 3480~3488). 그리고 중국을 중심으로 하여, 산자나무 Hippophae rhamnoides ssp. sinensis 15종, Hippophae rhamnoides ssp. yunnanensis 7종, Hippophae rhamnoides ssp. wolongensis 5종, Hippophae rhamnoides ssp. stellatopilosa 4종, Hippophae rhamnoides ssp. tibetana 3종에서 유래한 여러 가지 플라보노이드들을 HPLC 표준화작업에 의해 12종의 플라보노이드로 분류하여 이들의 다양성을 보고 하였다(J. of Chromatography A, Chu Chen, 1154, pp 250~259). 그리고 중국을 중심으로 여러 지역에서 자생하고 있는 각종 산자나무들로부터 성분 분리연구를 수행하여 분리된 12종의 플라보노이드들의 함량을 비교한 바 있다.
Hippophae rhamnoides, a plant of the Elaeagnaceae family, is found on the sand dunes of the eastern and southeastern coasts of Britain. It is a mountainous region in Europe and Asia, the Inner Mongolia region of China , And Siberia (Russia), and the Canadian Outback. The pharmacological activities of plant-derived flavonoids and glycosylated flavonoids are well known (Journal of antimicrobial chemotherapy, LC Chiang, W. Chiang, MC Liu and CC Lin, Vol. 52, pp 194-198, 2003). Many researchers have been conducting researches on active ingredients of lumber trees. Especially, the contents of various natural vitamins (A, B, C, E, P and K) were analyzed by quantitative and qualitative analysis and the contents of various amino acids and contents of various metals were analyzed. In addition, studies on the content of various nutrients and the study of fruit-related properties have been carried out as basic data for using the fruit of Sanjay as food (J. Agric. Food Chem., Vol. 47, pp 3480-3488). And mainly in China, Sanjay tree Hippophae rhamnoides ssp.
그러나, 상기 문헌의 어디에도 비타민나무 추출물을 유효성분으로 함유하는 정신적 스트레스관련 질환에 대한 억제활성에 대하여 개시되거나 교시된 바가 없다.
None of the above documents, however, discloses or teaches the inhibitory activity against mental stress-related diseases containing vitamin-A extract as an active ingredient.
이에 따라, 본 발명자들은 본 발명은 스트레스에 의한 스트레스 억제에 탁월한 천연물을 찾고자 연구한 결과, 비타민나무 추출물은 정신적 스트레스를 유발한 마우스를 이용한 동물 실험에서 마우스의 뇌 및 혈중 도파민(dopamine), 노르아드레날린(noradrenaline) 및 코르티코스테론(corticosterone)의 수준(level)을 저하시키고, 세로토닌(serotonin) 의 수준(level)이 증가시킴을 확인하여 정신적 스트레스관련 질환에 대한 억제, 예방 및 치료에 유용함을 확인하여 본 발명을 완성하였다.
Accordingly, the present inventors have found that natural extracts which are excellent for suppressing stress caused by stress can be used as an antioxidant. The inventors of the present invention have found that vitamin A extract is effective in suppressing the stress caused by mental stress in animal experiments using mouse brain and blood dopamine, it has been confirmed that it is useful for inhibiting, preventing and treating mental stress related diseases by confirming that the levels of noradrenaline and corticosterone are lowered and the level of serotonin is increased Thus completing the present invention.
상기 목적을 해결하기 위해 본 발명은 비타민나무 추출물을 유효성분으로 함유하는 정신적 스트레스 관련 질환의 치료 및 예방용 약학조성물을 제공한다. In order to solve the above-mentioned problems, the present invention provides a pharmaceutical composition for treating and preventing mental stress-related diseases containing vitamin-tree extract as an active ingredient.
또한 본 발명은 비타민나무 추출물을 유효성분으로 함유하는 정신적 스트레스 관련 질환의 개선 및 예방용 건강기능식품을 제공한다. The present invention also provides a health functional food for improving and preventing mental stress-related diseases containing vitamin-tree extract as an active ingredient.
본원에서 정의되는 상기 비타민나무는 열매, 줄기, 잎, 꽃, 뿌리, 전초 등, 바람직하게는 줄기 또는 잎 부위, 보다 바람직하게는 잎부위를 포함한다.The vitamin tree as defined herein includes fruit, stem, leaf, flower, root, outpost, preferably stem or leaf part, more preferably leaf part.
본원에서 정의되는 상기 추출물은 물, 주정, 탄소수 1 내지 4의 저급알코올 또는 이들의 혼합용매로부터 선택된 극성용매, 바람직하게는 물 및 주정 혼합용매, 보다 바람직하게는 물 또는 20 내지 90% 물 및 주정 혼합용매에 가용한 추출물을 포함한다.The extract as defined herein is a polar solvent selected from water, alcohol, lower alcohols having 1 to 4 carbon atoms or a mixed solvent thereof, preferably water and a mixed solvent, more preferably water or 20 to 90% water and alcohol Includes extracts soluble in mixed solvents.
본원에서 정의되는 상기 스트레스관련 질환은 정신적 스트레스로 기인한 질환을 통칭하며, 구체적으로는 우울증, 불안증, 불면증, 과다수면증, 기면증, 호흡곤란 수면장애, 일주기 리듬 수면장애, 악몽, 야경증, 몽유증 등의 수면장애, 보다 구체적으로는 우울증, 불안증 또는 불면증을 포함한다.
The stress-related disease as defined herein refers to a disease caused by mental stress, and specifically includes depression, anxiety, insomnia, hypersomnia, narcolepsy, difficulty sleeping in sleep, circadian rhythm sleep disorder, nightmares, Sleep disorders such as depression, more specifically depression, anxiety or insomnia.
이하, 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.
본 발명의 비타민나무 열매, 줄기, 꽃, 뿌리, 전초 등, 바람직하게는 줄기 또는 잎 재료를 동결 건조하여 마쇄한 후 시료 중량의 약 1 내지 100배, 바람직하게는 약 2 내지 20배에 달하는 부피의 물, 주정, 탄소수 1 내지 4의 저급알코올 또는 이들의 혼합용매로부터 선택된 극성용매, 바람직하게는 물 및 주정 혼합용매, 보다 바람직하게는 물 또는 1: 1-10 혼합비의 물 및 주정 혼합용매로 20 내지 120℃, 바람직하게는 30 내지 80℃에서 약 1 내지 72시간, 바람직하게는 2 내지 12시간 동안에서 열수 추출, 냉침 추출, 환류 냉각 추출 또는 초음파 추출 등의 추출방법을 사용하여, 바람직하게는 열수 추출하여 추출한 후 감압여과 및 농축하여 본 발명의 비타민나무 추출물들을 수득할 수 있다.A volume of about 1 to 100 times, preferably about 2 to 20 times the weight of the sample after freeze-drying the vitamins, stems, flowers, roots and outposts of the present invention, preferably stem or leaf material, Preferably a water and alcohol mixed solvent, more preferably water or a mixture of water and alcohol mixed in a ratio of 1: 1 to 10, selected from the group consisting of water, alcohol, lower alcohol having 1 to 4 carbon atoms, Preferably at a temperature of 20 to 120 캜, preferably 30 to 80 캜 for about 1 to 72 hours, preferably for 2 to 12 hours, using an extraction method such as hot water extraction, cold extraction, reflux cooling extraction or ultrasonic extraction Can be extracted with hot water, extracted, filtered under reduced pressure and concentrated to obtain the vitamin tree extract of the present invention.
또한 본 발명은 상기 제조방법 및 상기 제조방법으로 제조된 비타민나무 추출물을 유효성분으로 함유하는 정신적 스트레스 관련 질환의 치료 및 예방을 위한 약학 조성물 및 건강기능식품을 제공한다. The present invention also provides a pharmaceutical composition and a health functional food for the treatment and prevention of mental stress related diseases containing the vitamin tree extract prepared by the above production method and the above production method as an effective ingredient.
상기에서 제조된 비타민나무 추출물은 정신적 스트레스를 유발한 마우스를 이용한 동물 실험에서 마우스의 뇌 및 혈중 도파민(dopamine), 노르아드레날린(noradrenaline) 및 코르티코스테론(corticosterone)의 수준(level)을 저하시키고, 세로토닌(serotonin) 의 수준(level)이 증가시킴을 확인하여 정신적 스트레스관련 질환에 대한 억제, 예방 및 치료에 유용함을 확인하였다.The vitamin tree extracts prepared above reduce levels of dopamine, noradrenaline, and corticosterone in the brain and blood of mice in an animal experiment using a mouse that induced mental stress, It was confirmed that the level of serotonin was increased and thus it was found to be useful for inhibiting, preventing and treating mental stress related diseases.
본 발명의 조성물은, 조성물 총 중량에 대하여 상기 생약 추출물을 0.01 내지 99% 중량으로 포함한다.The composition of the present invention contains the herbal extract in an amount of 0.01 to 99% by weight based on the total weight of the composition.
그러나 상기와 같은 조성은 반드시 이에 한정되는 것은 아니고, 환자의 상태 및 질환의 종류 및 진행 정도에 따라 변할 수 있다.However, the composition is not limited thereto, and may vary depending on the condition of the patient, the type of disease, and the progress of the disease.
본 발명의 추출물을 포함하는 조성물은 약학적 조성물의 제조에 통상적으로 사용하는 적절한 담체, 부형제 및 희석제를 더 포함할 수 있다.Compositions comprising the extract of the present invention may further comprise suitable carriers, excipients and diluents conventionally used in the manufacture of pharmaceutical compositions.
본 발명에 따른 추출물을 포함하는 조성물은, 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있으며, 이에 포함될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 마그네슘 스테아레이트 및 광물유를 들 수 있다. 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 상기 화합물에 적어도 하나 이상의 부형제 적어도 면, 전분, 칼슘카보네이트(calcium carbonate), 수크로스(sucrose) 또는 락토오스(lactose), 젤라틴 등을 섞어 조제된다. 또한 단순한 부형제 이외에 마그네슘 스티레이트 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조제제, 좌제가 포함된다. 비수성용제, 현탁제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세롤젤라틴 등이 사용될 수 있다.The composition containing the extract according to the present invention may be formulated in the form of powders, granules, tablets, capsules, oral preparations such as suspensions, emulsions, syrups and aerosols, external preparations, suppositories and sterilized injection solutions, Examples of carriers, excipients and diluents that can be included in the composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium Silicates, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, magnesium stearate and mineral oil. In the case of formulation, a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, or a surfactant is usually used. Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient, such as starch, calcium carbonate, sucrose, Or lactose, gelatin, and the like. In addition to simple excipients, lubricants such as magnesium stearate talc are also used. Examples of the liquid preparation for oral use include suspensions, solutions, emulsions, and syrups. In addition to water and liquid paraffin, simple diluents commonly used, various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included . Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. As a suppository base, witepsol, macrogol, tween 61, cacao paper, laurin, glycerol gelatin and the like can be used.
본 발명의 추출물의 바람직한 투여량은 환자의 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 기간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다. 그러나 바람직한 효과를 위해서, 추출물은 1일 0.01 mg/kg 내지 10 g/kg으로, 바람직하게는 1 mg/kg 내지 1 g/kg으로 투여하는 것이 좋다. 투여는 하루에 한번 투여할 수도 있고, 수회 나누어 투여할 수 있다. 그러므로 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다.The preferred dosage of the extract of the present invention varies depending on the condition and the weight of the patient, the degree of disease, the type of drug, the administration route and the period of time, but can be appropriately selected by those skilled in the art. However, for the desired effect, the extract is preferably administered at a dose of 0.01 mg / kg to 10 g / kg per day, preferably 1 mg / kg to 1 g / kg per day. The administration may be carried out once a day or divided into several doses. Therefore, the dose is not intended to limit the scope of the present invention in any aspect.
본 발명의 조성물은 쥐, 생쥐, 가축, 인간 등의 포유동물에 다양한 경로로 투여될 수 있다. 투여의 모든 방식은 예상될 수 있는데, 예를 들면, 경구 및 직장 또는 정맥등의 방법을 통하여 투여 할 수 있다. The composition of the present invention may be administered to mammals such as rats, mice, livestock, humans, and the like in various routes. All modes of administration may be expected, including, for example, oral and rectal or intravenous administration.
또한 본 발명은 비타민나무 추출물을 유효성분으로 함유하는 정신적 스트레스 관련 질환의 개선 및 예방을 위한 건강기능식품을 제공한다. The present invention also provides a health functional food for improving and preventing mental stress-related diseases containing vitamin-tree extract as an active ingredient.
본 발명의 추출물을 포함하는 건강기능식품은 스트레스 관련 질환의 개선 및 예방을 위한 약제, 식품 및 음료 등에 다양하게 이용될 수 있다. 본 발명의 추출물을 첨가할 수 있는 식품으로는, 예를 들어, 각종 식품류, 음료, 껌, 차, 비타민 복합제, 침출차, 건강보조 식품류 등이 있고, 분말, 과립, 정제, 캡슐 또는 음료인 형태로 사용할 수 있다.The health functional food containing the extract of the present invention can be used variously for medicines, foods and beverages for the improvement and prevention of stress related diseases. Examples of the foods to which the extract of the present invention can be added include various foods, beverages, gums, tea, vitamin complex, leach tea, health supplement foods and the like, and they are in the form of powder, granule, tablet, capsule or beverage Can be used.
따라서 또한, 본 발명은 비타민나무 추출물을 유효성분으로 함유하는 정신적 스트레스 관련 질환의 개선 및 예방용 건강보조식품을 제공한다.Accordingly, the present invention also provides a health supplement for improving and preventing mental stress-related diseases containing vitamin-tree extract as an active ingredient.
따라서 또한, 본 발명은 비타민나무 추출물을 유효성분으로 함유하는 정신적 스트레스 관련 질환의 개선 및 예방용 식품첨가제를 제공한다.Accordingly, the present invention also provides a food additive for improving and preventing mental stress-related diseases containing vitamin-tree extract as an active ingredient.
본 발명의 추출물을 첨가 가능한 식품형태는 캔디류의 각종 식품류, 음료, 껌, 차, 비타민 복합제 또는 건강보조 식품류인 식품 등을 포함한다.The food forms to which the extract of the present invention can be added include various foods of candy, beverages, gums, tea, a vitamin complex, or foods that are health supplement foods.
본 발명의 추출물은 스트레스 억제 및 예방을 목적으로 식품 또는 음료에 첨가될 수 있다. 이 때, 식품 또는 음료 중의 상기 추출물의 양은 일반적으로 본 발명의 건강식품 조성물은 전체 식품 중량의 0.01 내지 15 중량%로 가할 수 있으며, 건강 음료 조성물은 100 ml를 기준으로 0.02 내지 10 g, 바람직하게는 0.3 내지 1 g의 비율로 가할 수 있다. The extract of the present invention can be added to food or beverage for the purpose of suppressing stress and preventing it. At this time, the amount of the extract in the food or beverage is generally 0.01 to 15% by weight of the total food weight of the health food composition of the present invention, and the health beverage composition is 0.02 to 10 g based on 100 ml, Can be added at a ratio of 0.3 to 1 g.
본 발명의 건강 음료 조성물은 지시된 비율로 필수 성분으로서 상기 추출물의 혼합물을 함유하는 것 외에 액체성분에는 특별한 제한점은 없으며 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등의 디사카라이드, 예를 들어 말토스, 슈크로스 등의 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 상술한 것 이외의 향미제로서 천연 향미제(타우마틴, 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진등)) 및 합성 향미제(사카린, 아스파르탐 등)를 유리하게 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100 ml당 일반적으로 약 1 내지 20 g, 바람직하게는 약 5 내지 12 g이다.The health beverage composition of the present invention may contain various flavors or natural carbohydrates as an additional ingredient, such as ordinary beverages, in addition to containing a mixture of the above extract as an essential ingredient in the indicated ratios, have. Examples of the above-mentioned natural carbohydrates include monosaccharides such as disaccharides such as glucose and fructose such as maltose, sucrose and the like and polysaccharides such as dextrin, cyclodextrin and the like Sugar, and sugar alcohols such as xylitol, sorbitol, and erythritol. As natural flavors other than those described above, natural flavors (such as tau martin, stevia extract (e.g., rebaudioside A, glycyrrhizin)) and synthetic flavors (saccharin, aspartame, etc.) have. The ratio of the natural carbohydrate is generally about 1 to 20 g, preferably about 5 to 12 g per 100 ml of the composition of the present invention.
상기 외에 본 발명의 조성물은 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있다. 그밖에 본 발명의 조성물들은 천연 과일 쥬스 및 과일 쥬스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 그렇게 중요하진 않지만 본 발명의 조성물 100 중량부 당 0 내지 약 20 중량부의 범위에서 선택되는 것이 일반적이다.
In addition to the above-mentioned composition, the composition of the present invention can be used as a flavoring agent such as various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, coloring agents and intermediates (cheese, chocolate etc.), pectic acid and its salts, Salts, organic acids, protective colloid thickening agents, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated beverages and the like. In addition, the compositions of the present invention may contain flesh for the production of natural fruit juices and fruit juice drinks and vegetable drinks. These components may be used independently or in combination. The proportion of such additives is not so critical, but is generally selected in the range of 0 to about 20 parts by weight per 100 parts by weight of the composition of the present invention.
본 발명의 비타민나무 추출물은 정신적 스트레스를 유발한 마우스를 이용한 동물 실험에서 마우스의 뇌 및 혈중 도파민(dopamine), 노르아드레날린(noradrenaline) 및 코르티코스테론(corticosterone)의 수준(level)을 저하시키고, 세로토닌(serotonin) 의 수준(level)이 증가시킴을 확인하여 정신적 스트레스관련 질환에 대한 억제, 예방 및 치료에 유용한 약학 조성물 또는 건강 기능 식품을 제공한다.
The vitamin-tree extract of the present invention lowers levels of dopamine, noradrenaline and corticosterone in the brain and blood of mice in an animal experiment using a mouse causing mental stress, the present invention provides a pharmaceutical composition or health functional food useful for inhibiting, preventing and treating mental stress related diseases by confirming that the level of serotonin is increased.
도 1은 약물처치 과정을 나타낸 도이며;
도 2는 비타민나무 추출물의 전기충격에 의한 스트레스 유도 마우스에서의 뇌 및 혈중 도파민 수준에 미치는 영향을 나타낸 도이며;(데이타는 평균(mean latencies) ± S.D. (n = 10)으로 표시하고. *** P < 0.001, ** P < 0.01, * P < 0.05 vs control임);
도 3는 비타민나무 추출물의 전기충격에 의한 스트레스 유도 마우스에서의 뇌 및 혈중 노르아드레날린 수준에 미치는 영향을 나타낸 도이며;(데이타는 평균(mean latencies) ± S.D. (n = 10)으로 표시하고. *** P < 0.001, ** P < 0.01, * P < 0.05 vs control임);
도 4는 비타민나무 추출물의 전기충격에 의한 스트레스 유도 마우스에서의 뇌 및 혈중 5-HT 수준에 미치는 영향을 나타낸 도이며;(데이타는 평균(mean latencies) ± S.D. (n = 10)으로 표시하고. *** P < 0.001, ** P < 0.01, * P < 0.05 vs control임);
도 5는 비타민나무 추출물의 전기충격에 의한 스트레스 유도 마우스에서의 뇌 및 혈중 코르티코스테론 수준에 미치는 영향을 나타낸 도이며;(데이타는 평균(mean latencies) ± S.D. (n = 10)으로 표시하고. *** P < 0.001, ** P < 0.01, * P < 0.05 vs control임);1 is a view showing a drug treatment process;
FIG. 2 is a graph showing the effect of vitamin-tree extract on brain and blood dopamine levels in stress-induced mice induced by electrical shock (data are expressed as means (mean latencies) ± SD (n = 10) * P <0.001, ** P <0.01, * P <0.05 vs control);
FIG. 3 is a graph showing the effect of vitamin-tree extract on brain and blood noradrenaline levels in stress-induced mice induced by electrical shock; data are expressed as mean latencies ± SD (n = 10) ** P <0.001, ** P <0.01, * P <0.05 vs control);
FIG. 4 is a graph showing the effect of vitamin-tree extracts on brain and blood 5-HT levels in stress-induced mice induced by electrical shock; data are expressed as mean latencies ± SD (n = 10). *** P <0.001, ** P <0.01, * P <0.05 vs control);
FIG. 5 is a graph showing the effect of vitamin-tree extract on brain and blood corticosterone levels in stress-induced mice induced by electrical shock; data are expressed as mean latencies ± SD (n = 10). *** P <0.001, ** P <0.01, * P <0.05 vs control);
이하, 본 발명을 하기 참고예 및 실험예에 의해 상세히 설명한다.Hereinafter, the present invention will be described in detail with reference to the following Reference Examples and Experimental Examples.
단, 하기 참고예 및 실험예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 참고예 및 실험예에 의해 한정되는 것은 아니다.
However, the following Reference Examples and Experimental Examples are merely illustrative of the present invention, and the content of the present invention is not limited by the following Reference Examples and Experimental Examples.
실시예Example
1. One.
비타민나무Vitamin tree
줄기 및 잎 추출물의 제조 Manufacture of stem and leaf extracts
1-1. 물 추출물의 제조1-1. Preparation of water extract
비타민나무 잎 (㈜참농비타민, 전남 장흥) 30 kg을 48시간 동안 동결 건조하여 저온건조하여 선별과정을 마친 후 분말화하고 상기 비타민나무 잎 분말 중량의 20배 부피의 물을 첨가하고 100℃에서 5시간 동안 추출기(COSMOS660,경서기계산업)로 환류추출 한 후 100 mesh의 여과망이 부착된 여과조를 이용하여 여과한 후 상등액을 감압 및 농축한 후에 동결 건조하여 비타민 나무 잎 열수 추출물(이하 HPW라 함)을 수득하여 하기 실험의 시료로 사용하였다.
30 kg of Vitamin tree leaf (Jeongnam Jangheung Co., Ltd.) was lyophilized for 48 hours, dried at low temperature, and powdered after finishing the selection process, water of 20 times the weight of the vitamin tree leaf powder was added, (COSMOS 660, Kyungseo Machinery Industry), filtered through a filter equipped with a 100-mesh filter, and the supernatant was concentrated under reduced pressure. The extract was lyophilized to give a hot-water extract of vitamin A (hereinafter referred to as HPW) Was used as a sample for the following experiment.
1-2. 주정 추출물의 제조1-2. Manufacture of alcohol extracts
비타민나무 잎 (㈜참농비타민, 전남 장흥) 30 kg을 48시간 동안 동결 건조하여 저온건조하여 선별과정을 마친 후 분말화하고 상기 비타민나무 잎 분말 중량의 20배 부피의 40% 주정을 첨가하고 100℃에서 5시간 동안 추출기(COSMOS660, 경서기계산업)로 환류추출 한 후 100 mesh의 여과망이 부착된 여과조를 이용하여 여과한 후 상등액을 감압 및 농축한 후에 동결 건조하여 비타민 나무 줄기 주정 추출물(이하 HPL라 함)을 수득하여 하기 실험의 시료로 사용하였다.
30 kg of Vitamin tree leaf (Jeongnam Jangheung Co., Ltd.) was lyophilized for 48 hours and dried at low temperature. After the selection process, it was powdered, and 40% of the weight of vitamin tree leaf powder was added to 40% (COSMOS660, Kyungshee Machinery Industry) for 5 hours. The filtrate was filtered through a filter equipped with a 100-mesh filter, and the supernatant was reduced in pressure and concentrated. The extract was freeze-dried to obtain Vitamin C truncate extract ) Was obtained and used as a sample in the following experiment.
실험예Experimental Example 1. One. 비타민나무Vitamin tree 추출물의 스트레스 완화 효과 확인 Identification of stress relieving effect of extract
상기 실시예에서 얻은 비타민나무 추출물의 족부 전기충격(electric foot shock)으로 스트레스를 유도한 후 혈청 및 뇌 주요 조직에서의 스트레스 관련 신경전달물질 및 호르몬(dopamine, noradrenaline, serotonin, corticosterone)의 함량 변화 측정을 통한 정신적 스트레스 완화 효과를 확인하기 위하여 문헌에 기재된 방법을 응용하여 하기와 같이 실험을 수행하였다 (Sang-Ki Park et al., Combination of Green Tea Extract and L-Theanine Alleviates Electric Foot Shock Induced Stress by Modulating Neurotransmitters in MiceYakhak Hoeji Vol. 53, No. 52, pp41~249, (2009))
Measurement of the content of stress-related neurotransmitters and hormones (dopamine, noradrenaline, serotonin, corticosterone) in the serum and brain main tissues after inducing stress by electric foot shock of the vitamin extracts obtained in the above Examples (Sang-Ki Park et al., Combination of Green Tea Extract and L-Theanine Alleviates Electric Foot Shock Induced Stress by Modulating) was applied in the following manner by applying the method described in the literature Neurotransmitters in Mice Yakhak Hoeji Vol. 53, No. 52, pp41 ~ 249 (2009))
1-1. 실험동물 및 시료1-1. Laboratory animals and samples
생후 6주 된 수컷 ICR mouse (20 ~ 25 g)를 중앙실험동물(주)로부터 구입하여, 1주간 순화시키면서 일반증상을 관찰하였고, 체중을 측정하여 건강한 것만을 선별하여 사용하였다. 실험동물은 충북대학교 실험동물연구지원센타에서 GLP 수준의 관리기준에 따라 수용하고, 관리, 투여, 실험을 실시하였다. 실험기간 중의 실험동물은 격리용 마우스 케이지당 3마리씩 수용하였고, 사육실 환경조건은 실내온도 23±3℃, 상대습도 55±10%, 조명시간 12시간(오전 7시~오후 7시), 조도 150~200 lux로 조절되었다. 물과 실험동물용 사료는 자유로이 섭취할 수 있도록 하였고, 시료를 물에 녹여 투여하기 위해 1일 평균 물 섭취량을 측정하였다.
Six - week - old male ICR mice (20-25 g) were purchased from the central laboratory animal, and general symptoms were observed for 1 week. The body weight was measured and only healthy ones were selected. Experimental animals were housed, managed, administered, and tested according to GLP level management standards at the Laboratory Animal Research Support Center of Chungbuk National University. The experimental animals were housed three times per cage for isolation. The environmental conditions of the cage were 23 ± 3 ℃, 55 ± 10%, 12 hours (7:00 am to 7:00 pm), 150 To 200 lux. The water and animal feeds were freely available and the average daily water intake was measured to dissolve the sample in water.
1-2. 시험물질 투여 및 용량 (표 1 및 도 1 참조)1-2. Test substance dosing and dosing (see Table 1 and Figure 1)
실험동물은 평균 체중과 분산이 균질하도록 군을 분리하고 각 군당 10마리로 하였으며, 양성대조군으로 디아제팜 (diazepam, Cat# D0899, Sigma, St. Louis, USA)을 2 mg/kg. b.w. 용량으로 스트레스 유도 30분 전에 1회 복강투여하였다. 테아닌 (teanin)과 비타민나무잎 열수 추출물의 경우 1일 1회 경구투여하였으며 총 31일 동안 투여하였다.The animals were divided into two groups: diazepam (Diazepam, Cat # D0899, Sigma, St. Louis, USA) at a dose of 2 mg / kg. b.w. Dose was intraperitoneally administered once 30 minutes before the induction of stress. In the case of teanin and vitamin A leaf hot water extract, it was orally administered once a day for a total of 31 days.
**I.P: intraperitoneally* bw: body weight
** IP: intraperitoneally
1-3. 스트레스 유도를 위한 전기자극1-3. Electrical Stimulation for Stress Induction
실험동물에 스트레스를 유도하는 방법으로서 문헌에 기재된 족부 전기충격(electric foot shock) 방법을 이용하였다. (Sang-Ki Park et al., Combination of Green Tea Extract and L-Theanine Alleviates Electric Foot Shock Induced Stress by Modulating Neurotransmitters in MiceYakhak Hoeji Vol. 53, No. 52, pp41~249, (2009))As a method of inducing stress in an experimental animal, a method of electric foot shock described in the literature was used. (Sang-Ki Park et al., Combination of Green Tea Extract and L-Theanine Alleviates Electric Foot Shock Induced Stress by Modulating Neurotransmitters in Mice Yakhak Hoeji Vol. 53, No. 52, pp41 ~
시험물질 투여 종료 후 족부 전기충격을 30분간 5초 간격으로 1초간 0.6 mA의 전기충격을 가하여 스트레스를 유도한 후 마우스를 부검, 혈액 및 뇌를 적출하였다.After the end of the test substance administration, stress was applied to the foot by electric shock of 0.6 mA for 1 second at intervals of 5 seconds for 30 minutes, and then mice were autopsied, blood and brain were excised.
시료 (theanin 및 비타민나무잎 열수 추출물)는 실험전일인 총 31일동안 경구투여 하였으며, diazepam의 경우 전기충격을 가하는 31일 째에만 복강투여 하였다.
Samples (theanin and vitamin A hydrothermal extracts) were orally administered for 31 days on the day before the experiment, and diazepam was administered intraperitoneally only on the 31st day of electric shock.
1-4.혈액 및 뇌의 채취 및 보관1-4 Collection and storage of blood and brain
스트레스 유도 후 5분 안에 실험동물을 에테르(ether)로 마취시킨 후 복부를 절개하여 1 ml syringe 로 복대동맥에서 심정지 직전까지 혈액을 채취하여 heparin 이 코팅되어 있는 blood collection vacutainer (BD, NJ, USA)에 넣어 잘 섞어준 후 상온에서 2시간을 방치하였다. 그 후 4℃, 15000 rpm에서 15분간 원심분리하여 상등액(plasma)을 분리하여 냉동보관(-20℃)하였다.After the induction of stress, the animals were anesthetized with ether and the abdomen was incised. The blood was collected from the abdominal artery to the immediate post-cardiac arrest with a 1-ml syringe, and the heparin-coated blood collection vacutainer (BD, And the mixture was allowed to stand at room temperature for 2 hours. The supernatant was centrifuged at 15,000 rpm for 15 minutes at 4 ° C, and the supernatant was separated and frozen (-20 ° C).
혈액이 제거된 마우스로부터 brain을 적출하였고, 여기에 200~500 μl의 extraction buffer (0.3 M sucrose, 0.15 mM spermine, 0.5 mM spermidine, 10 mM HEPES (pH 7.9), 1.5 mM MgCl2, 10mM KCl, 0.5mM DTT, 0.2mM PMSF, 0.1% protease inhibitor, 0.1% phosphatase inhibitor, 0.5% NP 40)를 넣어 균질화시킨 후 최종 부피가 1 ml이 되도록 extraction buffer를 가해 잘 혼합한 뒤 2시간 동안 4℃에서 lysis시켰다. 여기에 반응이 끝나면 시료를 1.5 ml tube에 담아 3분씩 5번 동안 vortex하고 4℃, 15,000 rpm에서 15분간 원심분리 한 후 상등액을 취하였다.
The brain was extracted from the blood-removed mouse and 200-500 μl of extraction buffer (0.3 M sucrose, 0.15 mM spermine, 0.5 mM spermidine, 10 mM HEPES (pH 7.9), 1.5
1-5. 생화학적 분석1-5. Biochemical analysis
분리/적출된 혈액 및 뇌조직내 dopamine(DA), noradrenaline(NE), serotonin(5-HT), corticosterone(CS)의 함량을 ELISA로 측정하였는데, Dopamine (Dopamine ELISA Kit, Cat# KA1887, Abnova Corp, Taipei City, Taiwan), Norepinephrine (Norepinephrine ELISA Kit, Cat# KA1891, Abnova Corp, , Taipei City, Taiwan), Serotonin (Serotonin ELISA Kit, Cat# KA1894, Abnova Corp, Taipei City, Taiwan), Corticosterone (Corticosterone ELISA Ki, Cat# KA0468, Abnova Corp, Taipei City, Taiwan)은 각각의 kit를 이용하여 제조사에서 제공한 실험방법에 따라 분석 하였다.
The contents of dopamine (DA), noradrenaline (NE), serotonin (5-HT) and corticosterone (CS) in the blood and brain tissues were measured by ELISA. Dopamine (Dopamine ELISA Kit, Cat # KA1887, Abnova Corp , Serotonin (Serotonin ELISA Kit, Cat # KA1894, Abnova Corp, Taipei City, Taiwan), Corticosterone (Corticosterone ELISA Kit, Taipei City, Taiwan), Norepinephrine (Norepinephrine ELISA Kit, Cat # KA1891, Abnova Corp, Ki, Cat # KA0468, Abnova Corp, Taipei City, Taiwan) were assayed according to the manufacturer's method using each kit.
1-6. 통계학적 분석1-6. Statistical analysis
실험의 결과는 평균 ± 표준편차로 표기하였고, 각 그룹간 차이는 Student's t-test 분석법을 사용하여 통계학적인 유의성을 판정하였으며 p값이 0.05 미만 (*p<0.05), 0.01 미만 (**p<0.01), 0.001 미만 (***p<0.001)인 경우를 구별하여 통계학적으로 유의성을 판단하였다.
Statistical significance was assessed using Student's t-test for differences between groups, p values <0.05 (* p <0.05), <0.01 (** p < 0.01) and less than 0.001 (*** p <0.001), and statistical significance was determined.
1-7. 실험 결과1-7. Experiment result
상기 실험 결과, 혈중 dopamine 수치는 스트레스 자극 전과 후에 유의적 차이가 없었으며, 양성대조군인 DZP theanin의 경우에도 별다른 변화를 확인 할 수 없었다. 시료인 비타민나무잎 열수 추출물을 투여한 군 모두 유의적 변화가 없었다. 뇌조직에서의 dopamine 수치는 30분 동안의 전기자극만을 준 control군 (86.72 ± 5.21 ng/mg protein)의 경우 뇌에서의 dopamine 수치가 스트레스 자극을 주지 않은 무처리군 (51.32 ± 3.15 ng/mg protein)과 비교하여 유의적으로 크게 증가한 것을 확인 하였다. 그리고 시료인 비타민나무 열수 추출물을 농도별로 처리 하였을 때, Low, Middle, High 군에서 각각, 80.41 ± 3.42, 77.43 ± 3.94, 71.42 ± 3.41 ng/mg protein으로 농도 의존적으로 dopamine 수치가 감소하는 것을 확인하였다. 양성대조군인 DZP (63.52 ± 4.72 ng/mg protein)와 theanine (73.31 ± 5.15 ng/mg protein)의 경우에도 증가된 dopamine 수치가 유의적으로 감소한 것을 확인하였다. 스트레스에 의해 증가된 dopamine 수준은 비타민나무 열수 추출물에 의해 유의적으로 감소하였다. (도 2 참조)As a result, the dopamine levels in the blood were not significantly different before and after the stress stimulation, and the positive control group, DZP theanin, did not show any significant change. There was no significant change in the vitamin - tree leaf hydrothermal extract group. In the control group (86.72 ± 5.21 ng / mg protein), the dopamine levels in the brain tissue were significantly higher than those in the control group (51.32 ± 3.15 ng / mg protein ) Compared with the control group. In addition, when treated with the extract of vitamin wood hydrothermal extract, the concentration of dopamine decreased by 80.41 ± 3.42, 77.43 ± 3.94 and 71.42 ± 3.41 ng / mg protein in the Low, Middle and High groups, respectively . Significant reductions in dopamine levels were also observed in the positive control DZP (63.52 ± 4.72 ng / mg protein) and theanine (73.31 ± 5.15 ng / mg protein). The levels of dopamine increased by stress were significantly decreased by vitamin A hydrothermal extract. (See Fig. 2)
Electric Foot Shock로 정신적 스트레스를 가한 후, 비타민나무잎 열수 추출물이 serum 에서의 noradrenalin 수준에 미치는 영향을 측정하였다. 30분 동안의 전기자극만을 준 control군 (71.52 ± 7.32 ng/mg protein)의 경우 혈중에서의 noradrenalin 수치가 스트레스 자극을 주지 않은 무처리군 (32.51 ± 4.74 ng/mg protein)과 비교하여 유의적으로 크게 증가한 것을 확인 하였다. 그리고 시료인 비타민나무 열수 추출물을 농도별로 처리 하였을 때, Middle, High 군에서 각각, 56.41 ± 3.94, 54.17 ± 4.12 ng/mg protein으로 농도 의존적으로 noradrenalin 수치가 감소하는 것을 확인하였다. 양성대조군인 DZP (45.73 ± 4.32 ng/mg protein)와 theanine (53.35 ± 3.24 ng/mg protein)의 경우에도 증가된 noradrenalin 수치가 유의적으로 감소하였다. 뇌조직에서의 noradrenalin 수치도 전기자극만을 준 control군 (105.11 ± 7.52 ng/mg protein)의 경우 스트레스 자극을 주지 않은 무처리군 (31.47 ± 3.15 ng/mg protein)과 비교하여 유의적으로 크게 증가한 것을 확인 하였다. 그리고 시료인 비타민나무 열수 추출물을 농도별로 처리 하였을 때, Low, Middle, High 군에서 각각, 87.43 ± 5.15 88.13 ± 3.94, 78.32 ± 4.51 ng/mg protein으로 농도 의존적으로 noradrenalin 수치가 감소하는 것을 확인하였다. 양성대조군인 DZP (62.72 ± 6.14 ng/mg protein)와 theanine (81.12 ± 5.15 ng/mg protein)의 경우에도 증가된 noradrenalin 수치가 유의적으로 감소한 것을 확인하였다. 스트레스에 의해 증가된 noradrenalin 수준은 비타민나무 열수 추출물에 의해 유의적으로 감소하였다. (도 3 참조)After applying mental stress to Electric Foot Shock, the effect of vitamin A hydrothermal extract on serum noradrenalin levels was measured. In the control group (71.52 ± 7.32 ng / mg protein), which had only electrical stimulation for 30 minutes, the level of noradrenalin in the blood was significantly higher than that of the untreated group (32.51 ± 4.74 ng / mg protein) Respectively. The concentration of noradrenalin was decreased by 56.41 ± 3.94 and 54.17 ± 4.12 ng / mg protein in the middle and high groups, respectively. Increased noradrenalin levels were also significantly reduced in the positive control DZP (45.73 ± 4.32 ng / mg protein) and theanine (53.35 ± 3.24 ng / mg protein). The level of noradrenalin in the brain tissue was significantly increased in the control group (105.11 ± 7.52 ng / mg protein) compared to the no-treatment group (31.47 ± 3.15 ng / mg protein) Respectively. When the extracts of Vitamin A hydrothermal extract were treated at different concentrations, 87.43 ± 5.15 88.13 ± 3.94 and 78.32 ± 4.51 ng / mg protein in the Low, Middle and High groups showed a decrease in noradrenaline levels in a concentration-dependent manner. Significant reductions in noradrenalin levels were also observed in the positive controls, DZP (62.72 ± 6.14 ng / mg protein) and theanine (81.12 ± 5.15 ng / mg protein). The level of noradrenalin increased by stress was significantly decreased by vitamin hydrothermal extract. (See Fig. 3)
serum 에서의 5-HT 수준에 미치는 영향을 측정하였을 때, 30분 동안의 전기자극만을 준 control군 (10.33 ± 2.46 ng/mg protein)의 경우 뇌에서의 5-HT 수치가 스트레스 자극을 주지 않은 무처리군 (21.31 ± 2.11 ng/mg protein)과 비교하여 유의적으로 크게 감소한 것을 확인하였다. 그리고 시료인 비타민나무 열수 추출물을 농도별로 처리 하였을 때, High 군에서 17.12 ± 3.14 ng/mg protein으로 5-HT 수치가 유의적으로 증가 하는 것을 확인하였다. 양성대조군인 DZP (28.43 ± 3.31 ng/mg protein)와 theanine (16.64 ± 2.14 ng/mg protein)의 경우에도 감소한 5-HT 수치가 유의적으로 증가한 것을 확인하였다. 뇌조직에서의 5-HT의 수준도 전기자극만을 준 control군 (14.43 ± 5.21 ng/mg protein)의 경우 뇌에서의 5-HT 수치가 스트레스 자극을 주지 않은 무처리군 (34.42 ± 3.15 ng/mg protein)과 비교하여 유의적으로 크게 감소한 것을 확인 하였다. 그리고 시료인 비타민나무 열수 추출물을 농도별로 처리 하였을 때, 각각 Middle, High 군에서 23.35 ± 3.94, 32.35 ± 3.41 ng/mg protein으로 5-HT 수치가 유의적으로 증가 하였다. 양성대조군인 DZP (42.36 ± 4.72 ng/mg protein)와 theanine (28.42 ± 3.36 ng/mg protein)의 경우에도 감소한 5-HT 수치가 유의적으로 증가한 것을 확인하였다. 특히 DZP의 경우, 무처리군 수준으로 5-HT 함량이 크게 증가 하였으며,스트레스에 의해 감소한 5-HT 수준은 비타민나무 열수 추출물에 의해 유의적으로 다시 증가하였다. (도 4 참조)When 5-HT levels in serum were measured, the 5-HT levels in the brain in the control group (10.33 ± 2.46 ng / mg protein), which only received 30 minutes of electrical stimulation, Compared with the control group (21.31 ± 2.11 ng / mg protein). When 5-HT levels of 17.12 ± 3.14 ng / mg protein were significantly increased in the high-group treated with the vitamin-tree hydrothermal extract, The decrease in 5-HT levels was also significantly increased in the positive control DZP (28.43 ± 3.31 ng / mg protein) and theanine (16.64 ± 2.14 ng / mg protein). The levels of 5-HT in brain tissues were significantly higher in the control group (14.43 ± 5.21 ng / mg protein) than in the control group (34.42 ± 3.15 ng / mg) in the brain without stress stimulation protein) significantly decreased compared to the control group. The 5-HT levels were significantly increased by 23.35 ± 3.94 and 32.35 ± 3.41 ng / mg protein in the middle and high groups, respectively. The decrease in 5-HT levels was also significantly increased in the positive control DZP (42.36 ± 4.72 ng / mg protein) and theanine (28.42 ± 3.36 ng / mg protein). In particular, in the case of DZP, the 5-HT content was significantly increased at the level of the untreated group, and the 5-HT level decreased by the stress was significantly increased again by the vitamin hydrothermal extract. (See Fig. 4)
Electric Foot Shock로 정신적 스트레스를 가한 후, 비타민나무잎 열수 추출물이 serum 에서의 corticosterone 수준에 미치는 영향을 측정하였다. 30분 동안의 전기자극만을 준 control군 (32.25 ± 2.89 ng/mg protein)의 경우 뇌에서의 corticosterone 수치가 스트레스 자극을 주지 않은 무처리군 (9.51 ± 3.15 ng/mg protein)과 비교하여 유의적으로 크게 증가한 것을 확인 하였다. 그리고 시료인 비타민나무 열수 추출물을 농도별로 처리 하였을 때, Middle, High 군에서 각각, 24.73 ± 3.94, 24.43 ± 3.41 ng/mg protein으로 corticosterone 수치가 유의적으로 감소 하는 것을 확인하였다. 양성대조군인 DZP (13.36 ± 2.35 ng/mg protein)와 theanine (21.14 ± 3.24 ng/mg protein)의 경우에도 증가한 corticosterone 수치가 유의적으로 감소하는 것을 확인하였다. 뇌조직에서의 corticosterone의 수준도 30분 동안의 전기자극만을 준 control군 (1562 ± 140.32 ng/mg protein)의 경우 뇌에서의 corticosterone 수치가 스트레스 자극을 주지 않은 무처리군 (154.35 ± 35.36 ng/mg protein)과 비교하여 유의적으로 크게 증가한 것을 확인 하였다. 그리고 시료인 비타민나무 열수 추출물을 농도별로 처리 하였을 때, Low, Middle, High 군에서 각각, 1251.36 ± 84.42, 1152.36 ± 84.35, 1095.45 ± 79.64 ng/mg protein으로 corticosterone 수치가 유의적으로 감소 하는 것을 확인하였다. 양성대조군인 DZP (625.32 ± 105.35 ng/mg protein)와 theanine (984.43 ± 94.35 ng/mg protein)의 경우에도 증가한 corticosterone 수치가 유의적으로 감소하는 것을 확인하였다. 스트레스에 의해 감소한 corticosterone 수준은 비타민나무 열수 추출물에 의해 유의적으로 감소하였다. (도 5 참조)After applying mental stress with Electric Foot Shock, the effect of vitamin A hydrothermal extract on serum corticosterone levels was measured. In the control group (32.25 ± 2.89 ng / mg protein), which had only 30 minutes of electrical stimulation, corticosterone levels in the brain were significantly higher than those in the untreated group (9.51 ± 3.15 ng / mg protein) Respectively. When corticosterone extracts were treated at the concentrations of 24, 233 ± 3.94 and 24.43 ± 3.41 ng / mg protein in the middle and high groups, the corticosterone levels were significantly decreased. The increase in corticosterone levels was also significantly reduced in the positive control group, DZP (13.36 ± 2.35 ng / mg protein) and theanine (21.14 ± 3.24 ng / mg protein). The level of corticosterone in brain tissue was significantly higher in the control group (1562 ± 140.32 ng / mg protein) than in the electrical stimulation group for 30 minutes (154.35 ± 35.36 ng / mg protein) protein significantly increased compared to the control group. When the extracts of Vitamin A hydrothermal extract were treated at different concentrations, the levels of corticosterone were significantly decreased in the Low, Middle and High groups by 1251.36 ± 84.42, 1152.36 ± 84.35, and 1095.45 ± 79.64 ng / mg protein, respectively . The increase in corticosterone levels was also significantly reduced in the positive control group, DZP (625.32 ± 105.35 ng / mg protein) and theanine (984.43 ± 94.35 ng / mg protein). The corticosterone levels decreased by stress were significantly decreased by vitamin A hydrothermal extract. (See Fig. 5)
결론적으로 비타민나무 추출물은 정신적 스트레스를 유발한 마우스를 이용한 동물 실험에서 마우스의 뇌 및 혈중 도파민(dopamine), 노르아드레날린(noradrenaline) 및 코르티코스테론(corticosterone)의 수준(level)을 저하시키고, 세로토닌(serotonin) 의 수준(level)이 증가시킴을 확인하여 정신적 스트레스 억제에 효과가 있는 기능성 소재로써 판단되며, 향후 대사적 기작관련 연구를 추가 수행하여 기능성 소재로써 매우 유용하게 이용될 수 있다.
In conclusion, vitamin A extracts lowered levels of mouse brain and blood dopamine, noradrenaline and corticosterone levels in mice in mental stress-induced animals, and serotonin serotonin levels in the brain, and thus it is considered to be a functional material effective for suppressing mental stress. The present invention can be used as a functional material by performing additional metabolic mechanism studies.
하기에 본 발명의 추출물을 포함하는 조성물의 제제예를 설명하나, 본 발명은 이를 한정하고자 함이 아닌 단지 구체적으로 설명하고자 함이다.
Hereinafter, formulation examples of the composition containing the extract of the present invention will be described, but the present invention is not intended to be limited thereto but will be specifically described.
제제예Formulation example 1. One. 산제의Sanje 제조 Produce
HPW ------------------------------------------------- 200 mgHPW ------------------------------------------------- 200 mg
유당 ------------------------------------------------ 100 mgLactose ------------------------------------------------ 100 mg
탈크 ------------------------------------------------- 10 mgTalc ------------------------------------------------- 10 mg
상기의 성분들을 혼합하고 기밀포에 충진하여 산제를 제조한다.
The above components are mixed and filled in airtight bags to prepare powders.
제제예Formulation example 2. 정제의 제조 2. Preparation of tablets
HPL ------------------------------------------------- 200 mgHPL ------------------------------------------------- 200 mg
옥수수전분 ------------------------------------------ 100 mgCorn starch ------------------------------------------ 100 mg
유당 ------------------------------------------------ 100 mgLactose ------------------------------------------------ 100 mg
스테아린산 마그네슘 ----------------------------------- 2 mgMagnesium stearate ----------------------------------- 2 mg
상기의 성분들을 혼합한 후 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조한다.
After mixing the above components, tablets are prepared by tableting according to the usual preparation method of tablets.
제제예Formulation example 3. 캅셀제의 제조 3. Preparation of capsules
HPW ------------------------------------------------- 200 mgHPW ------------------------------------------------- 200 mg
결정성 셀룰로오스 ------------------------------------- 3 mgCrystalline cellulose - 3 mg
락토오스 ------------------------------------------- 14.8 mgLactose ------------------------------------------- 14.8 mg
마그네슘 스테아레이트 ------------------------------- 0.2 mgMagnesium Stearate ------------------------------- 0.2 mg
통상의 캅셀제 제조방법에 따라 상기의 성분을 혼합하고 젤라틴 캡슐에 충전하여 캅셀제를 제조한다.
The above components are mixed in accordance with a conventional method for producing a capsule, and filled in a gelatin capsule to prepare a capsule.
제제예Formulation example 4. 주사제의 제조 4. Preparation of injections
HPL ------------------------------------------------- 200 mgHPL ------------------------------------------------- 200 mg
만니톨 ---------------------------------------------- 180 mgMannitol ---------------------------------------------- 180 mg
주사용 멸균 증류수 --------------------------------- 2974 mgSterile sterile distilled water for injection --------------------------------- 2974 mg
Na2HPO4 ,12H2O ------------------------------------------ 26 mgNa 2 HPO 4 , 12H 2 O ------------------------------------------ 26 mg
통상의 주사제의 제조방법에 따라 1 앰플당 (2 ㎖) 상기의 성분 함량으로 제조한다.
(2 ml) per ampoule in accordance with the usual injection method.
제제예Formulation example 5. 5. 액제의Liquid 제조 Produce
HPW ------------------------------------------------- 200 mgHPW ------------------------------------------------- 200 mg
이성화당 ---------------------------------------------- 10 gIsolation Party ---------------------------------------------- 10 g
만니톨 ------------------------------------------------- 5 gMannitol ------------------------------------------------- 5 g
정제수 ------------------------------------------------ 적량Purified water ------------------------------------------------
통상의 액제의 제조방법에 따라 정제수에 각각의 성분을 가하여 용해시키고 레몬향을 적량 가한 다음 상기의 성분을 혼합한 다음 정제수를 가하여 전체를 정제수를 가하여 전체 100 ml로 조절한 후 갈색병에 충진하여 멸균시켜 액제를 제조한다.
Each component was added and dissolved in purified water according to the usual liquid preparation method, and the lemon flavor was added in an appropriate amount. Then, the above components were mixed, and purified water was added thereto. The whole was added with purified water to adjust the total volume to 100 ml, And sterilized to prepare a liquid preparation.
제제예Formulation example 6. 건강 식품의 제조 6. Manufacture of health food
HPL ------------------------------------------------ 1000 mgHPL ------------------------------------------------ 1000 mg
비타민 혼합물 ----------------------------------------- 적량Vitamin mixture -----------------------------------------
비타민 A 아세테이트 ---------------------------------- 70 ㎍Vitamin A Acetate ---------------------------------- 70 g
비타민 E -------------------------------------------- 1.0 ㎎Vitamin E -------------------------------------------- 1.0 mg
비타민 B1 ------------------------------------------ 0.13 ㎎Vitamin B1 ------------------------------------------ 0.13 mg
비타민 B2 ------------------------------------------ 0.15 ㎎Vitamin B2 ------------------------------------------ 0.15 mg
비타민 B6 ------------------------------------------- 0.5 ㎎Vitamin B6 ------------------------------------------- 0.5 mg
비타민 B12 ------------------------------------------ 0.2 ㎍Vitamin B12 ------------------------------------------ 0.2 g
비타민 C --------------------------------------------- 10 ㎎Vitamin C --------------------------------------------- 10 mg
비오틴 ----------------------------------------------- 10 ㎍Biotin ----------------------------------------------- 10 μg
니코틴산아미드 -------------------------------------- 1.7 ㎎Nicotinic acid amide 1.7 mg
엽산 ------------------------------------------------- 50 ㎍Folic acid ------------------------------------------------- 50 [mu] g
판토텐산 칼슘 --------------------------------------- 0.5 ㎎Calcium pantothenate --------------------------------------- 0.5 mg
무기질 혼합물 ----------------------------------------- 적량Inorganic mixture -----------------------------------------
황산제1철 ------------------------------------------ 1.75 ㎎Ferrous sulfate ------------------------------------------ 1.75 mg
산화아연 ------------------------------------------- 0.82 ㎎Zinc oxide - 0.82 mg
탄산마그네슘 --------------------------------------- 25.3 ㎎Magnesium carbonate --------------------------------------- 25.3 mg
제1인산칼륨 ------------------------------------------ 15 ㎎
제2인산칼슘 ------------------------------------------ 55 ㎎Calcium Phosphate - 55 mg
구연산칼륨 ------------------------------------------- 90 ㎎Potassium citrate ------------------------------------------- 90 mg
탄산칼슘 -------------------------------------------- 100 ㎎Calcium carbonate -------------------------------------------- 100 mg
염화마그네슘 --------------------------------------- 24.8 ㎎Magnesium Chloride --------------------------------------- 24.8 mg
상기의 비타민 및 미네랄 혼합물의 조성비는 비교적 건강식품에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 그 배합비를 임의로 변형 실시하여도 무방하며, 통상의 건강식품 제조방법에 따라 상기의 성분을 혼합한 다음, 과립을 제조하고, 통상의 방법에 따라 건강식품 조성물 제조에 사용할 수 있다.
Although the composition ratio of the above-mentioned vitamin and mineral mixture is comparatively mixed with a composition suitable for health food as a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional method for producing healthy foods , Granules can be prepared and used in the manufacture of health food compositions according to conventional methods.
제제예Formulation example 7. 건강 음료의 제조 7. Manufacture of health drinks
HPW ----------------------------------------------- 1000 mgHPW ----------------------------------------------- 1000 mg
구연산 -------------------------------------------- 1000 ㎎Citric acid -------------------------------------------- 1000 mg
올리고당 -------------------------------------------- 100 gOligosaccharides -------------------------------------------- 100 g
비타민나무농축액 -------------------------------------- 2 gVitamin tree concentrate -------------------------------------- 2 g
타우린 ------------------------------------------------ 1 gTaurine ------------------------------------------------ 1 g
정제수를 가하여 ------------------------------- 전체 900 ㎖Add purified water - 900 ml total
통상의 건강음료 제조방법에 따라 상기의 성분을 혼합한 다음, 약 1시간 동안 85℃에서 교반 가열한 후, 만들어진 용액을 여과하여 멸균된 2 ℓ 용기에 취득하여 밀봉 멸균한 뒤 냉장 보관한 다음 본 발명의 건강음료 조성물 제조에 사용한다. The above components were mixed according to a conventional health drink manufacturing method, and the mixture was stirred and heated at 85 ° C for about 1 hour. The resulting solution was filtered to obtain a sterilized 2-liter container, which was sealed and sterilized, It is used in the production of the health beverage composition of the invention.
상기 조성비는 비교적 기호음료에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 수요계층, 수요국가, 사용용도 등 지역적, 민족적 기호도에 따라서 그 배합비를 임의로 변형 실시하여도 무방하다.Although the composition ratio is a mixture of the components suitable for the preferred beverage as a preferred embodiment, the blending ratio may be arbitrarily varied according to the regional and national preferences such as the demand level, the demanding country, and the intended use.
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020140140470A KR101676828B1 (en) | 2014-10-17 | 2014-10-17 | A composition comprising an extract of Hippophae rhamnoides for treating or preventing a physiological stress, depression or dementia |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020140140470A KR101676828B1 (en) | 2014-10-17 | 2014-10-17 | A composition comprising an extract of Hippophae rhamnoides for treating or preventing a physiological stress, depression or dementia |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20160045256A KR20160045256A (en) | 2016-04-27 |
KR101676828B1 true KR101676828B1 (en) | 2016-11-15 |
Family
ID=55914572
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020140140470A KR101676828B1 (en) | 2014-10-17 | 2014-10-17 | A composition comprising an extract of Hippophae rhamnoides for treating or preventing a physiological stress, depression or dementia |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101676828B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102226052B1 (en) | 2019-11-13 | 2021-03-10 | (주)마스터피스 | A anti-stress, anxiolytic and anti-depressant formula comprising L-theanine and bee pollen |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110559322A (en) * | 2018-06-06 | 2019-12-13 | 邹玮 | Sea-buckthorn compound hard capsule for treating depression and preventing anxiety depression and preparation method thereof |
-
2014
- 2014-10-17 KR KR1020140140470A patent/KR101676828B1/en active IP Right Grant
Non-Patent Citations (1)
Title |
---|
Farhat Batool. et al, `Evaluation of antidepressant-link effects of aqueous extract of Sea Buckthorn(Hippophae rhamnoides L. ssp. turkestanica) fruits in experimental models of depression', Pak. J. Bo* |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102226052B1 (en) | 2019-11-13 | 2021-03-10 | (주)마스터피스 | A anti-stress, anxiolytic and anti-depressant formula comprising L-theanine and bee pollen |
Also Published As
Publication number | Publication date |
---|---|
KR20160045256A (en) | 2016-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100680121B1 (en) | Formulation containing lyso-phosphatidylserine for the prevention and treatment of stress states in warm-blooded animals | |
US20060286181A1 (en) | Diet supplements for causing fast weight loss, improving daytime energy, promoting nighttime relaxation and sleep, controlling appetite and/or increasing metabolism | |
KR20140120667A (en) | A composition comprising the extract of Salix genus plant for treating and preventing neuro-degenerative disease | |
KR102225574B1 (en) | Composition for preventing, treating or improving obesity or obesity-related disease comprising extracts of Angelica tenuissima | |
KR101685438B1 (en) | A composition comprising an extract of Hippophae rhamnoides for improving physical fatigue, and exercise performance ability | |
KR101676828B1 (en) | A composition comprising an extract of Hippophae rhamnoides for treating or preventing a physiological stress, depression or dementia | |
KR101401612B1 (en) | Composition comprising extract of punica granatum for prevention and treatment of stress diseases | |
KR101779536B1 (en) | Composition for treating sleep disorder and enhacning sleeping time containing polygonatum extract | |
KR100692402B1 (en) | A pharmaceutical composition comprising the extract of gardenia for treating or preventing depression disease | |
KR100867612B1 (en) | Composition comprising sungnoiwon for improving brain function and memory dysfunction | |
KR100526631B1 (en) | Composition comprising the extract of Morus alba L having monoamine oxidase-inhibiting activity | |
KR101151567B1 (en) | Composition comprising the extract of mixed crude drug showing anti-allergic Effect | |
KR101862836B1 (en) | Pharmaceutical composition comprising heracleum moellendorffii hance extract for preventing or treating depression | |
KR101130030B1 (en) | Composition comprising the extract of Gastodia elata Blume for preventing and treating PD | |
KR20110072745A (en) | Composition comprising the extract of prunella vulgaris l for preventing and treating adhd | |
KR20130090936A (en) | A composition and functional food comprising an extracts of rosa rugosa preventing or treating a stress-involved disease caused by sleep deprivation | |
KR100526628B1 (en) | Composition comprising the extract of Morus alba L having monoamine oxidase-inhibiting activity | |
KR20110064917A (en) | Composition comprising the extract of flos hemerocallis fulva for preventing and treating depression | |
KR20120055159A (en) | A composition for reducing sleep induction time and prolonging sleeping time containing chrysanthemum indicum extract, and preparing method for the same | |
KR101929353B1 (en) | Composition comprising the extract of Sprouts Valerian fauriei having anti-depressant activity | |
KR100561251B1 (en) | Composition comprising the extract of Glycine max having monoamine oxidase-inhibiting activity | |
KR100750877B1 (en) | A pharmaceutical composition comprising the extract of green tea for treating or preventing depression disease | |
KR101568044B1 (en) | Composition reducing anxiety and stress | |
KR102240706B1 (en) | A composition for sleep induction comprising Passiflora incarnata extract | |
KR100679319B1 (en) | A pharmaceutical composition comprising the extract of dandelion for treating or preventing depression disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20191107 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20200109 Year of fee payment: 5 |